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ABSTRACT
Infliximab, a chimeric monoclonal antibody (mAb) against tumor necrosis factor (TNF)-a, has shown activity
against steroid refractory acute graft-versus-host disease (aGVHD). We conducted a prospective trial of inflix-
imab for the prophylaxis of aGVHD. Patients older than 20 years undergoing myeloablative allogeneic stem cell
transplantation (SCT) for hematologic malignancies were eligible. GVHD prophylaxis consisted of infliximab
given 1 day prior to conditioning and then on days 0,17,114,128, and142, together with standard cyclospor-
ine (CSA) and methotrexate (MTX). Nineteen patients with a median age of 53 years were enrolled. All patients
received peripheral blood allografts from matched sibling (n 5 14) or unrelated donors (n 5 5). Results were
compared with a matched historic control group (n5 30) treated contemporaneously at our institution. The cu-
mulative incidences of grades II-IV aGVHD in the infliximab and control groups were 36.8% and 36.6%, respec-
tively (P5 .77). Rates of chronic GVHDwere 78% and 61%, respectively (P5 .22). Significantly more bacterial
and invasive fungal infections were observed in the infliximab group (P5 .01 and P5 .02, respectively). Kaplan-
Meier estimates of 2-year overall survival (OS) and progression free survival (PFS) for patients receiving inflix-
imab were 42% and 36%, respectively. The corresponding numbers for patients in the control group were 46%
and 43%, respectively. The addition of infliximab to standard GVHD prophylaxis did not lower the risk of
GVHD and was associated with an increased risk of bacterial and invasive fungal infections.
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Acute graft-versus-host disease (aGVHD) is 1 of
themost frequent complications after allogeneic hema-
topoietic stem cell transplantation (HSCT) [1]. Over-
production of tumor necrosis factor-a (TNF-a) is
implicated in the pathophysiology of aGVHD through
several mechanisms including upregulation of the ex-
pression of major histocompatibility complex antigens,
endothelial cell and leukocyte adhesion molecules,
induction of target tissues apoptosis through TNF-a
receptor, activation of macrophages, neutrophils,eosinophils, B cells and T cells, and increased produc-
tion of additional inflammatory cytokines [2-4]. Ele-
vated serum levels of TNF-a are seen in patients with
aGVHD, and may be predictive of the severity of
GVHD [5,6].
Infliximab (Remicade, Centocor, Malvern, PA) is
a murine-human chimeric IgG1k monoclonal anti-
body (mAb) that binds with high affinity to the soluble
and transmembrane forms of TNF-a, and inhibits
their binding with the cellular receptors [7]. A number
of retrospective studies have shown activity of this drug783
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generally employing high doses (10 mg/kg/week). Al-
though no prospective clinical trial of infliximab for
the prophylaxis of aGVHDhas been reported, neutral-
izing anti-TNF-a mAb administered prior to TBI in
murine models have shown significantly delayed mor-
tality and improved body weight in treated mice [11].
We theorized that infliximab may decrease the risk
of aGVHD, and therefore conducted a prospective
trial to evaluate the efficacy and toxicity of infliximab
prophylaxis prior to allogeneic stem cell transplant.
PATIENTS, MATERIALS, AND METHODS
Patient Population
Beginning in April 2004, 19 patients were enrolled
at the time of allogeneic transplant for acute myeloge-
nous leukemia (AML), myelodysplastic syndrome
(MDS), acute lymphoblastic leukemia/lymphoma,
non-Hodgkin lymphoma (NHL), Hodgkin’s lym-
phoma (HL), or chronic myelogenous leukemia
(CML) in the accelerated phase or blast crisis. Patients
undergoing HSCT for CML in the chronic phase or
aplastic anemia (AA) were not eligible. CML patients
in the chronic phase were excluded because these pa-
tients generally have favorable outcomes with standard
GVHD prophylaxis (cyclosporine [CsA] 1 methotrex-
ate [MTX]), and more intense GVHD prophylaxis in
this group may increase the risk of disease relapse post-
transplantation [12]. Patients with acute leukemia in the
first complete remission, MDS with refractory anemia,
or refractory anemia with ringed sideroblasts were con-
sidered to have low-risk disease. All other patients were
placed in the high-risk disease category. Patients with
human immunodeficiency virus seropositivity, Karnof-
sky performance status\60%, and those receiving re-
duced-intensity conditioning (RIC) were excluded.
The study was approved by the Ohio State University
institutional review board, and all patients underwent
informed consent.
The patients enrolled in this study were compared
with an historic control group of 30 patients who had
undergone allogeneic HSCT at our center at approxi-
mately the same time as the study group (between
January 2003 and October 2005), and who had either
not consented to the study or were not eligible because
of insurance denial. Matching criteria for control
group selection included diagnosis, pretransplant dis-
ease status, and risk category, age, stem cell source,
myeloablative conditioning with TBI or busulfan con-
taining regimen, GVHD prophylaxis, donor type, and
degree of HLA match.
HLA Typing and Donor Matching
In patients with sibling donors HLA typing for
class I antigens was performed using standard serologic
techniques. Typing for Class II alleles (HLA-DRB1)was resolved with sequence-specific oligonucleotide
primers for hybridization of amplified DNA, followed
by high-resolution typing in all patients and donors.
Unrelated donors were matched for HLA-A, -B, and
-DRB1 by high-resolution typing.
Treatment Protocol
Infliximab was administered as a 120-minute infu-
sion at 10 mg/kg the day before the conditioning reg-
imen. Five subsequent doses were given on days
0 (after hematopoietic stem cell infusion), 17, 114,
128, and 142. No dose modifications were done for
renal or hepatic impairment. All patients received stan-
dard prophylaxis of aGVHD with CsA (3 mg/kg/day
i.v., commencing on day 21) and short-course MTX
(15 mg/m2 day 1, and 10 mg/m2 days 3, 6, and 11). Cy-
closporine levels were maintained between 150 and
450 ng/mL. From day 1100 onward CsA was tapered
at the discretion of the treating physician.
Transplantation Procedure and Supportive Care
All patients received myeloablative conditioning
regimens using either TBI (1200 cGy) or busulfan (16
mg/kg oral or 12.8 mg/kg i.v.) in combination with
other drugs.Donor cellswere infused onday 0. Patients
weremonitoredweekly for cytomegalovirus (CMV) re-
activation with Digene hybrid capture assay. Gancy-
clovir or foscarnet were used at the discretion of the
treating physician for patients with evidence of CMV
reactivation. Filgastrim granulocyte-colony stimulat-
ing factor (G-CSF) was not routinely administered.
CMV negative products were used for CMV seronega-
tive patients. Neutrophil engraftment was defined as
the first of 3 successive days after transplantation,
with ANC $0.5  109/L. Platelet engraftment was
considered tohaveoccurredon thefirst of 3 consecutive
days with platelet count 20  109/L or higher, in the
absence of platelet transfusion.
Assessment of GVHD
Staging and grading of aGVHD were scored ac-
cording to consensus criteria [13]. Biopsies of all in-
volved organs were required to corroborate the
clinical diagnosis of aGVHD. Exception was patients
with multiorgan aGVHD where liver biopsy was pre-
ferred but not required. Liver-only GVHD required
biopsy confirmation. Patients were evaluable for
chronic GVHD (cGVHD) if engraftment occurred
and the patient survived for 100 days posttransplanta-
tion. Assessments were made according to previously
described criteria [14].
Adverse Events
Adverse events were assessed and recorded after
HSCT for an evaluation of safety. Veno-occlusive dis-
ease (VOD) was diagnosed and graded according to
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Clinical Trial (N 5 19) Control Group (N 5 30)
N (%) N (%) P-Value*
Median age, years (range) 53 (27-64) 43.5 (21-64) .05
Sex
Male 13 (68) 20 (67) .99
Female 6 (32) 10 (33)
Stem cell source
PBSC 19 (100) 30 (100) —
BM 0 0
Donor source
HLA-matched related 14 (74) 25 (83) .49
HLA-mismatched related 0 (0) 1 (3)
HLA-matched unrelated 4 (21) 2 (7)
HLA-mismatched unrelated 1 (5) 2 (7)
Diagnosis
MDS/AML 11 (58) 21 (70) .26
Non-Hodgkin lymphoma 4 (21) 3 (10)
ALL 4 (21) 3 (10)
HOD 0 3 (10)
Disease risk
Standard risk 8 14 .75
High risk 11 16
Sex match
Sex matched 9 (47) 16 (54) .86
Male to female 4 (22) 7 (23)
Female to male 6 (31) 7 (23)
ABO matched/mismatched
Matched 11 (58) 20 (67) .14
Major mismatch 5 (26) 2 (7)
Minor mismatch 3 (16) 8 (26)
Median CD341 cell dose (106 cells/kg recipient wt) 4.95 5.22 .70
Median CD31 cell dose (107 cells/kg recipient wt) 2.94 3.02 .72
G-CSF used
Yes 12 (63) 13 (43) .24
No 7 (37) 17 (57)
Conditioning regimen
TBI-containing 4 (21) 3 (10) .41
Bu/Cy 15 (79) 27 (90)
ALL indicates acute lymphoblastic lymphoma;AML, acutemyelogenous leukemia, BM, bonemarrow;Bu/Cy, busulphan and cyclophosphamide;
G-CSF, granulocyte colony stimulating factor; HOD, Hodgkin lymphoma; MDS, myelodysplastic syndrome; PBSC, peripheral blood stem
cells; TBI, total body irradiation.
*P-values are based on Wilcoxon rank-sum for medians and Fisher’s Exact test for categoric data.McDonald et al. [15] and Bearman [16] criteria, re-
spectively. Infections were documented as ‘‘proven’’
if an organism was isolated or confirmed by serologic,
molecular, culture, or histologic evidence, or ‘‘sus-
pected’’ if patients developed fevers and radiologic or
clinical evidence of infection without organism identi-
fied. Urine and/or serum BK-virus PCR was obtained
in all suspected cases of hemorrhagic cystitis. Primary
cause of death and treatment related (nonrelapse) mor-
tality (TRM) were defined according to National
Marrow Donor Program criteria [17].
Statistical Analysis
The primary efficacy outcome for this study was
cumulative incidence of grade II-IV aGVHD within
100 days of allogeneic HSCT. Secondary objectives
included incidence of cGVHD, TRM, overall survival(OS), progression free survival (PFS), adverse events,
and infectious complications. Competing risk analysis
between aGVHD and TRM were used to estimate the
cumulative incidence. PFS rates were calculated using
death and disease progression as events. Actuarial
survival after transplantation was evaluated by the
Kaplan-Meier method. Predictors of response were
evaluated by logistic regression. Predictors of survival
were evaluated by Cox proportional hazards model.
Categoric variables and aGVHD incidence between
the study group and the historic control group were
compared by using the chi-square test or Fisher exact
test, as appropriate; continuous variables were com-
pared by using the Mann-Whitney test, and OS and
PFS data were analyzed by the log-rank test. Cumula-
tive incidence of aGVHD between infliximab and his-
torical controls was compared using Gray’s test. All
786 M. Hamadani et al.analyses were run using Stata 10.0 (Stata Corporation,
College Station, TX).
RESULTS
Patient and Disease Characteristics
Twenty-four consecutive patients provided in-
formed consent for enrollment in the infliximab group.
Five patients did not receive infliximab for GVHD
prophylaxis secondary to insurance denial, and are
not included in the final analysis. The remaining 19 pa-
tients constitute the infliximab group, while 30
matched historical controls were selected. Demo-
graphics and transplant characteristics of both groups
are summarized in Table 1. Compared to patients re-
ceiving infliximab, the control group was slightly
younger (median age 43.5 versus 53 years, P-value 5
.05). All patients in the control group received
aGVHD prophylaxis with short-course methotrexate
and cyclosporine. No patient in either group received
a T cell-depleted graft.
Engraftment
There were no engraftment failures in either
group. The median time to neutrophil engraftment
was 16 days (range: 12-27 days) for patients in the in-
fliximab groups and 14 days (range: 11-23 days) in
the control group (P-value 5 .06). Two and 3 patients
in the infliximab and control group failed to meet the
criteria for platelet engraftment, respectively. The me-
dian time to platelet engraftment in the infliximab
group (26 days, range: 14-99 days) was significantly
longer (P-value 5 .02) compared to the control group
(16 days, range: 13-47 days).
Acute GVHD
The cumulative incidence of grade II-IV aGVHD
(Figure 1) was 36.8% in the infliximab group (n 5 7)
and 36.6% in the control group (n5 11) (P-value5 .77).
Figure 1. Cumulative incidence of acute grade II-IV GVHD (black
and gray curves depict infliximab-treated and control groups, respec-
tively) Gray’s test P-value 5 .77.The distribution of aGVHD grades in both groups is
presented in Table 2. No difference in the incidence
of aGVHDwas seen among the 2 groups, across all se-
verity grades (P-value 5 .22). On multivariate logistic
regression analysis adjusted for patient age, sex, degree
of HLA-compatibility, donor type, and conditioning
regimen, no difference in odds of developing aGVHD
between the infliximab and control group was found
(P-value 5 .94, 95% confidence interval 0.13-3.55).
Median time to onset of aGVHD in the infliximab
and control groups was 30 and 32 days, respectively
(P-value 5 .4). Within the infliximab group no differ-
ence (P-value5 .70) was seen in themedian time to the
onset of aGVHD in patients conditioned with TBI-
containing regimens (29 days) versus those receiving
non-TBI-based conditioning (31 days). Distribution
of organ involvement was similar between the 2
groups. Among patients undergoing transplantation
from sibling donors the rates of grade II-IV aGVHD
in the infliximab and control groups were 35.7% (n
5 5) and 30.7% (n 5 8), respectively (P-value 5 .75),
whereas the corresponding rates of grade II-IV
aGVHD in recipients of allografts from unrelated
donors in the infliximab and control groups were
40% (n 5 2) and 75% (n 5 3), respectively (P-value
5 .29). Interestingly, subgroup analysis of patients in
the infliximab group according to disease risk cate-
gories revealed that 7 of 11 patients with high-risk dis-
ease (63%) developed grade II-IV aGVHD, whereas
none of the 8 patients with standard-risk disease devel-
oped grade II-IV aGVHD (P-value5 .004). Five of 16
patients with high-risk disease in the control group
(31%) developed grade II-IV aGVHD. This was not
significantly different from rates seen in high risk pa-
tients in the infliximab group (P-value 5 .09). How-
ever, among patients with standard-risk disease
infliximab produced significantly better control of
grade II-IV aGVHD (0%) compared to the control
group (42%) (P-value 5 .02).
Chronic GVHD
Fourteen patients in the infliximab group and 26 in
the control group were evaluable for cGVHD. In
patients receiving infliximab prophylaxis, the inci-
dence of cGVHD was 78% (n 5 11), compared to
61% (n 5 16) in the control group (P-value 5 .22).







0 9 (47.3) 10 (33.3)
I 3 (15.7) 9 (30)
II 1 (5.2) 7 (23.3)
III 3 (15.7) 2 (6.6)
IV 3 (15.7) 2 (6.6)
aGVHD indicates acute graft-versus-host disease.
Infliximab and aGVHD Prophylaxis following Allogeneic PBCT 787Nine patients in the infliximab group and 11 in the
control group had extensive cGVHD (P-value 5 .44).
Toxicity and Infections
Four patients did not receive all of the planned 6
doses of infliximab. Reasons of discontinuation in-
cluded: development of grade III-IV aGVHDwhile still
receiving infliximab prophylaxis (n 5 2), disease pro-
gression in the central nervous system in a patient with
Burkitt lymphoma (n 5 1) and overwhelming sepsis
(n 5 1). No allergic or infusion-related adverse events
were attributed to infliximab. Similarly, no neurologic
or cardiac complications attributable to infliximab de-
veloped. No cases of posttransplant lymphoproliferative
disease, second malignancies, tuberculosis, or atypical
mycobacterium developed. Noninfectious complica-
tions possibly related to infliximab included: nausea/
vomiting (n5 1), fatigue (n5 1), diarrhea (n5 1), night
sweats (n 5 1), pulmonary fibrosis (n5 1), acute respi-
ratory distress syndrome (n5 2), transient renal insuffi-
ciency (n 5 2), shortness of breath (n 5 1), pleural
effusion (n 5 1) and gastric bleeding (n 5 1).
Infectious complications were frequent. Table 3
summarizes proved infections among patients in the
infliximab and control group. Five patients developed
invasive fungal infections including; invasive pulmo-
nary aspergillosis (n5 2), candidemia (n5 1), pulmo-
nary candidiasis (n 5 1) and candida urinary tract
infection (n 5 1) in the infliximab group. Compared
to the control group, invasive fungal infections were
significantly more frequent in the infliximab group
(P-value 5 .03). Viral infections in the infliximab
group included CMV reactivation (n 5 13), BK vi-
Table 3. Infections in Patients Receiving Infliximab Prophylaxis and
Control Group








Staphylococcus aureus 6 (31) 3 (10)
Staphylococcus (not aureus) 11 (58) 11 (37)
Enterococcus 3 (16) 5 (16)
Clostridium difficile 5 (26) 7 (23)
Other 3 (16) —
Gram-negative 8 (42) 10 (33)
Fungal
Candida glabrata 2 (10) 0
Candida spp 1 (5) 0
Aspergillus spp 2 (10) 1 (3)
Viral
Cytomegalovirus 13 (68) 18 (60)
BK-virus 4 (21) 3 (10)
Adenovirus — —
Epstein-Barr virus — 1 (3)
Others 1 (5) 1 (3)rus-associated hemorrhagic cystitis (n 5 4), and vari-
cella zoster virus reactivation (n 5 1). One patient
developed CMV pneumonitis. In contrast in the
control group, 18 patients developed CMV reactiva-
tion and 3 had BK virus-associated hemorrhagic cysti-
tis. In addition, 1 episode each of influenza A and EBV
reactivation was seen in the control group. No signifi-
cant difference between the 2 groups was present in
terms of viral infections (P-value 5 .90). In the inflixi-
mab group, 18 patients (95%) developed a total of 40
bacterial infectious events (including 26 episodes of
bacteremias, 3 urinary tract infections, 7 episodes of
Clostridium difficile colitis, and 4 respiratory tract infec-
tions). In the control group, 19 patients (63%) devel-
oped a total of 39 bacterial infections (P-value 5 .01).
Outcomes
Seven patients in the infliximab group are alive at
a median follow-up of 34 months (range: 21-42
months). All surviving patients have cGVHD (6 pa-
tients have extensive cGVHD), and display no evidence
of disease progression. Twelve of 19 enrolled patients
died. Causes of death included disease relapse (n 5 6),
GVHD (n 5 3), pulmonary invasive fungal infections
in patients with GVHD (n 5 2) and sepsis with multi-
organ failure (n 5 1). The Kaplan-Meier estimates of
OS at 2 years after transplantation were 42% in the in-
fliximab group and 46% in the control group (P-value
5 .49) (Figure 2). Similarly, estimates of the 2-year
PFS between the 2 groups were 36% and 43%, re-
spectively (P-value 5 .50) (Figure 3). Six patients in
the infliximab group experienced disease relapse
(31%) compared to 10 patients (33%) in the control
group (P-value 5 .89). No significant difference in the
day 100 TRM rates between infliximab (21%) and
control (13%) groups was seen (P-value 5 .47). Two-
year TRM rates were 31% (n 5 6) and 26% (n 5 8)
in the infliximab and control groups, respectively
(P-value 5 .76).
Figure 2. Kaplan-Meier estimates of OS (black and gray curves
depict infliximab-treated and control groups, respectively) Log-
rank P-value 5 .43.
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Despite recent advances, GVHD remains a signifi-
cant barrier toward broader and safer application of al-
logeneic HSCT. Effective prophylaxis of aGVHD
remains crucial for improving allogeneic transplant
outcomes. The role of TNF-a in the pathogenesis of
aGVHD is supported by successful prevention of mu-
rine GVHD by neutralizing polyclonal TNF-a anti-
body before TBI and allografting [3,11]. Although
infliximab has shown activity in steroid refractory
aGVHD [8-10,18,19], it has not been formally evalu-
ated as a prophylactic agent for aGVHD.
Holler et al. [20] reported delayed onset and sever-
ity of aGVHD disease (especially in patients receiving
TBI-based conditioning) with MAK 195F, a murine
monoclonal antibody neutralizing human TNF-a (not
available in United States) compared to historic con-
trols. In contrast, we did not detect any significant dif-
ference in the incidence, severity, or time to onset of
aGVHD following incorporation of infliximab into
a standard GVHD prophylaxis regimen. Standard
aGVHD prophylaxis used in both studies was identical
(CsA and MTX). These paradoxical GVHD-related
outcomes reported in our study compared to those re-
ported by Holler et al. might be secondary to unknown
biologic differences between these 2 TNF-a blocking
agents. Patient selection may have a role. Interestingly,
the MAK 195F trial included younger patients (median
age, 45.2 years) with matched sibling donors and the
majority of enrolled patients had CML in the first
chronic phase. In contrast, our patients were older,
the majority had high-risk disease (n 5 11), and in-
cluded those receiving unrelated donor grafts.
TNF-a has shown no protective effects on devel-
opment of cGVHD in murine models [3]. No statisti-
cally significant impact of TNF-a antibody on
cGVHD was seen in the MAK 195F study [20]. In
our trial, a statistically nonsignificant trend toward
Figure 3. Kaplan-Meier estimates of PFS (black and gray curves
depict infliximab-treated and control groups, respectively) Log-
rank P-value 5 .50.increased GVHD was seen with infliximab use. In-
creased incidence of cGVHD in 90% of patients re-
ceiving infliximab for steroid refractory aGVHD has
been reported previously [8].
Infliximab use in our study was associated with sig-
nificantly delayed engraftment of platelets and a trend
toward delayed neutrophil engraftment as well. TNF-
a has been shown to strongly augment interleukin-3-in-
duced short-term proliferation of human CD341
hematopoietic progenitor cells [21]. Abrogation of
this effect might lead to delayed engraftment seen in
our study. Delayed neutrophil and platelet engraftment
was also apparent in the MAK 195F study, especially in
cohorts receiving higher doses of TNF- antibody [20].
There has been an increase in infectious complications
with the use of infliximab in patients with steroid refrac-
tory aGVHD [8,18,19]. Marty et al. [22] reported a sig-
nificantly increased risk of invasive fungal infections
with infliximab (45%) in patients with steroid refractory
GVHD compared to those not exposed to the drug
(12%). However, patients in these studies with steroid
refractory GVHD were profoundly immunocompro-
mised. Nevertheless, infliximab use in our study, as pro-
phylaxis of aGVHD, was associated with a significantly
increased incidence of fungal and bacterial infections.
The dose of infliximab employed in our study for
GVHD prophylaxis (10 mg/kg) was selected based
on the dose used in the majority of the studies report-
ing infliximab’s efficacy in steroid-refractory aGVHD,
and is higher compared to the infliximab dose (5 mg/
kg) recommended for rheumatologic indications
[8,9,18,19,23-26]. We did not perform any pharmaco-
kinetic sampling, and therefore it is possible that other
dosing schemes might be more effective in this setting.
The frequent infectious complications seen in our
study might be secondary to the dose and administra-
tion schedule of infliximab; however, such infectious
events are well documented, even with standard
(5 mg/kg) infliximab dosing schedules [23,25,27]. This
study has several limitations. Prospectively enrolled
patients who received infliximab for aGVHD prophy-
laxis were compared to matched historic controls pre-
viously treated in our institution. Although the control
group was well matched, this type of analysis is con-
founded by inherent selection bias. Nevertheless, im-
portant conclusions can be drawn. Infliximab use did
not produce a significant improvement in the cumula-
tive incidence of aGVHD, may have delayed platelet
engraftment, and was associated with frequent infec-
tious complications. Infliximab is unlikely to make
a major impact in controlling and preventing aGVHD
following myeloablative conditioning at least in
patients with high-risk hematologic malignancies.
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